Aruvant Sciences, Inc.

Palani Palaniappan, Ph.D., Stephen Hoffman, M.D., Ph.D., and Paul Westberg, MBA, bring deep industry experience to guide Company growth COLUMBUS, Ohio--(BUSINESS WIRE)-- Clarametyx Biosciences Inc. (“Clarametyx”), a clinical stage biotechnology company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the appointment of Palani Palaniappan, Ph.D., to its Scientific Advisory Board, as well as the appointments of Stephen Hoffman, M.D., Ph.D. and Paul Westberg, MBA as strategic advisors. “We are humbled to welcome Dr. Palaniappan to our scientific advisory board, as his extensive industry knowledge will not only augment our scientific focus but introduce critical development expertise that will enable us to pursue the full potential for our novel anti-biofilm technology,” said David Richards, Chief Executive Officer. “We are also pleased to engage Stephen Hoffman, MD, Ph.D. and Paul Westberg, MBA, who will further enhance our corporate and strategic development activities as we build momentum toward the next phase of the company’s growth.” Palani Palaniappan is an experienced business leader passionate about developing innovative and impactful medicines for patients. He is currently Chief Technology Officer of Pioneering Medicines at Flagship Pioneering. Dr. Palaniappan previously served as the Executive Vice President and Chief Technology Officer at Aruvant Sciences. His prior executive roles included Head of Global Technical Operations at Sarepta Therapeutics and Global Head of Biologics and New Modality Development at Takeda Pharmaceuticals. His early career included leadership positions at Millennium Pharmaceuticals (acquired by Takeda), Biogen, Nexstar Pharmaceuticals (acquired by Gilead), and Par Pharmaceuticals. Palani received his Ph.D. from the Indian Institute of Technology, Kanpur and completed his post-doctoral studies in biochemistry and biophysics at the University of California, Riverside and Virginia Commonwealth University. He holds a M.S. and B.S. from Annamalai University. Stephen Hoffman is a seasoned life sciences executive with over 30 years of experience building companies and leading entrepreneurial teams to create shareholder value. He is currently a Managing Partner and Co-Founder of Trekk Venture Partners and serves on multiple public and private company boards. He was previously the CEO of Aerpio Pharmaceuticals, Inc. and Allos Therapuetics, Inc. and served as Managing Director at Skyline Ventures, as well as General Partner at TVM Capital. Paul Westberg is a strategic business executive with more than 25 years of broad transactions, financing, market planning, and advisory experience focused on advancing transformational therapies in the life sciences sector. He was most recently the Chief Business Officer of Qpex Biopharma, a resistance-focused infectious disease company, which was acquired by Shionogi. Earlier in his career, Mr. Westberg was Chief Business Officer at Versartis and has previously served in numerous business development and finance roles for start-up companies since starting his career at Genentech. Mr. Westberg received his MBA from the University of California, Berkeley and his BA from the University of California, San Diego. About Clarametyx Biosciences Clarametyx Biosciences is combating the formidable challenge of persistent and recalcitrant infections through an innovative technology platform targeting the biofilm—a protective layer around bacteria—to enable a more effective immune response and antibiotic intervention. The Columbus, Ohio-based company is building a dynamic pipeline of immune-enabling therapies and vaccines for life-threatening bacterial infections associated with biofilms, with a near-term focus on challenging respiratory infections. For more information, visit us on the web or on LinkedIn.

DUBLIN--( BUSINESS WIRE )--The "Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023" report has been added to ResearchAndMarkets.com's offering. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies. This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2016. There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments. Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal. Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project. The report provides a detailed understanding and analysis of how and why companies enter joint venture deals. Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. This report contains a comprehensive listing of all joint venture deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal. The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal. Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals. Chapter 4 provides a review of the leading Joint venture deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database. Chapter 5 provides a comprehensive listing of the top 25 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal. The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2016. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document. The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2016. In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances. Key benefits Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 provides the reader with the following key benefits: In-depth understanding of joint venture partnering deal trends since 2016, with real life case studies Comprehensive listing of all joint venture deals since 2016, together with deal terms, value and press release Comprehensive access to actual joint venture contracts entered into by the world's life science companies Insight into the terms included in a joint venture agreement, together with real world clause examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 is intended to provide the reader with an in-depth understanding of the joint venture trends and structure of deals entered into by leading life science companies worldwide. Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 includes: Trends in joint venture dealmaking in the biopharma industry since 2016 Case studies of real-life joint venture deals Comprehensive listing of joint venture deals since 2016 Access to joint venture contract documents The leading joint venture deals by value since 2016 Most active joint venture dealmakers since 2016 The leading joint venture partnering resources In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 available deals and contracts are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand. The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2016-2023 report provides comprehensive access to available contract documents for joint venture deals. Companies Mentioned 3SBio 1717 Life Science Ventures A*STAR Agency for Science Technology and Research A*STAR Institute of Microelectronics (IME) A*STAR' Institute of Molecular and Cell Biology A2A Pharmaceuticals AAP Implantate AG Abbott Laboratories Abbvie Abilita Bio ABIVAX Abzena Accellix Accuray Acnos Pharma Adept Neuro Adisseo Advanced Prenatal Therapeutics Advanced Technologies Solutions Aequus Pharmaceuticals Agilis Biotherapeutics AgonOx AirWare Labs Aitbiotech Akers Biosciences AKESOgen Aleafia Health Aleva Neurotherapeutics Allied-Bristol Life Sciences Allied Minds Ally Bridge Group Altus Formulation Alzheimer's Association Alzheimer's Research UK Amarantus BioSciences Amendia American Diabetes Association AmerisourceBergen Amunix Amyris AnaBios Anokion Antitope Antoxerene Apax Partners Aphria Arbele Arbutus ARCH Personalized Medicine Initiative Aridis Pharmaceuticals Aruvant Sciences Arvinas Ascendance Biotechnology Ascendis Pharma Asklepios Biopharmaceutical Aslan Pharma Astellas Pharma AstraZeneca ATAI Life Sciences Athenex ATL Technology Atomwise Atrapos Therapeutics Atropos Therapeutics Auramedi Farmaceutica Autobio Diagnostics AUT Roche Diagnostics Laboratory AUT University Auxly Cannabis Group Avacta Avactis Biosciences Avalon GloboCare Avivagen Avvinity Therapeutics Axis Therapeutics Bain Capital Baxter International Bayer Baylor College of Medicine Baylor Miraca Genetics Laboratories B Braun B Braun CeGaT Beckley Canopy Therapeutics Beckley Foundation Becton Dickinson BeiGene Beijing Genomics Institute (BGI) Beijing Leadman Biochemistry Berry Genomics Betaliq BevCanna BGI Tech Solutions BHB Therapeutics Bill and Melinda Gates Foundation Bio-Techne BioAmber Biodist Biodyne USA BioFields Biogen Biohealth Innovation BioHeart BioLife Solutions BioLight BiolineRX biologistex CCM BioMed X Innovation Center Biomerics BioMotiv BioPharma Services Blackstone Blockshine Technology Bloomage BioTechnology Bloom Burton BLP Management Blueberries Medical Boehringer Ingelheim Breakthrough Diagnostics Brigham and Women's Hospital Bristol-Myers Squibb Broad Institute Buchang Pharmaceutical Buck Institute for Age Research Bukwang Pharmaceuticals Button Capital Calysta Energy Cancer Research Technology Cannabics Pharmaceuticals Cannabis Biocare Cannabis Therapeutics CannAmerica Brands CannaRoyalty Canopy Health Innovations Capna Intellectual Capnia Cardio3 Biosciences Asia Holdings Casebia Therapeutics Catapult Therapy TCR CB2 Therapeutics CBDerma Technology CBDistribution Cedar Gate Technologies CeGaT Cell Therapy Catapult Celyad Centauri Therapeutics Centene Center for Genetic Engineering and Biotechnology (Cuba) Centre for Commercialization of Regenerative Medicine (CCRM) Centro de Inmunolgia Molecular Cerevel Therapeutics Cesca Therapeutics Chan Soon-Shiong Institute of Molecular Medicine ChemAxon Children's Medical Research Institute Chimera Biotec China-Israel Biological Technology China-Singapore Guangzhou Knowledge City China Isotope And Radiation Chinese Academy of Science Chinese Future Industry Investment Fund Chongqing PSK-Health Sci-tech Development Cincinnati Children's Hospital Medical Center City of Hope CJ CheilJedang ClearPath Cloaked Therapeutics Co-Diagnostics Cohen Veterans Bioscience Cold Spring Harbor Colibri Heart Valve Collagen Solutions Plc Columbus Venture Partners Concentrics Research Consortium AI Corestone Biosciences Cornerstone Animal Health Corning Covenant Animal Health Partners Cre8ive CRISPR Therapeutics CureCell Cyclica CytoBioscience Cytotheryx Cytovant Sciences Daewoong Pharmaceutical Dance Biopharm Dasman Diabetes Institute David Snow Deerfield Management DemeRx Demetra Denka Denka-KEW Genomics DepYmed DIAN Diagnostics Diavax Biosciences Dixi Dizal Pharmaceutical DolCas-Tenshi Bioceuticals DolCas Biotech Dona Blanca Dongbao Dr. Walter Bell Duke-NUS Graduate Medical School Singapore Eastar Industries Eastern Capital Easton Pharmaceuticals eCardio Diagnostics Eddingpharm Eden BioCell Elanix Biotechnologies Elevar Therapeutics Eli Lilly EMD Millipore EMD Serono Emergence Therapeutics EmoCellix Emory University Emosis Enigma Diagnostics Enova Illumination Entheogenix Biosciences ERS Genomics Evotec ExCellThera Exemplar Genetics Facebook Faes Farma Faxian Therapeutics Fedecore Fedora Pharmaceuticals FerGene Ferring Pharmaceuticals FJ Pharma Flexpoint Ford Flow Pharma Fonterra Food and Drug Administration (FDA) FORMA Therapeutics Fortress Biotech Fosun Pharmaceutical FoxBio Fox Chase Cancer Center Fraunhofer Institute for Microelectronic Circuits and Systems Frazier Healthcare Ventures Fresenius Kabi Pharmaceuticals Frontage Laboratories FSD Pharma Futura Medical Fuzionaire Diagnostics Fuzionaire Radioisotope Technologies G-treeBNT Galectin Sciences Galectin Therapeutics Galvani Bioelectronics Gauss Surgical Genentech Gene Therapy Research Institution Genetic Technologies Genevant Sciences Genome Institute of Singapore Genomix Scientific Gentag GeoVax German Research Center for Artificial Intelligence Gerresheimer GHO Capital Ginkgo BioWorks GlaxoSmithKline For more information about this report visit https://www.researchandmarkets.com/r/laae8e About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

None  Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer or Gabrielle Masson, and we will feature it here at the end of each week.  David Kessler resigns from the Biden admin, marking the unofficial end of Operation Warp Speed The White House David Kessler, M.D., is resigning as chief scientific officer of the Biden administration’s COVID response, marking the end of Operation Warp Speed, the famed federal effort to develop and administer COVID vaccines. His departure is a tangible checkpoint in the COVID-19 pandemic, as COVID vaccinations transition from being organized and overseen by the federal government to the private sector. In an exit interview with The Wall Street Journal, Kessler said, “There has never been a successful vaccine campaign as large as this.”  Kessler’s resignation marks the end of his latest chapter in public service, which began in 1990 when President George H.W. Bush appointed him to be commissioner of the FDA. He served in the role until 1997 when he stepped down, later becoming dean of the Yale School of Medicine.  Kessler’s role as chief scientific officer of the pandemic response was much different than that of his predecessors in the prior administration. Whereas leaders of Operation Warp Speed worked on expediting development of COVID vaccines, Kessler was in charge of administration. And over the last three years, more than 650 million doses have been administered. And while new infections and hospitalizations have remained lower than prior highs, efforts to roll out new booster shots have proved more difficult. Tweet Novocure shakes up C-suite as tumor-treating field pipeline expands Novocure  Cancer-treating medical device company Novocure is shaking up its executive team as the company’s chief medical officer steps down following a “review of Novocure’s future needs.” The decision by Ely Benaim, M.D., comes days after the company posted a positive readout of a phase 3 trial testing its tumor treating fields in conjunction with standard therapy as a treatment for non-small cell lung cancer. Now, the company is reorganizing its ranks. Taking Benaim’s spot temporarily is Senior Vice President and Head of Global Medical Affairs Piet Hinoul, M.D., Ph.D. Benaim will work with the company’s executive team to help with the transition while an external search for his replacement continues. He’ll report to Pritesh Shah, who himself is transitioning from chief commercial officer to chief growth officer. Similarly, Chief Scientific Officer Uri Weinberg, M.D., Ph.D., is set to become the new chief innovation officer, a position that’s described as looking into new ways to expand use of the tumor treating fields. Taking Weinberg’s place is SVP of preclinical research Moshe Giladi, Ph.D. Source AstraZeneca’s Marshall takes over as Juvenescence CEO  Juvenescence Richard Marshall, M.D., a longtime British Big Pharma executive, is taking the reins at aging-focused biotech Juvenescence. His move marks the end of a three-and-a-half year career at AstraZeneca where he most notably oversaw development of the company’s COVID-19 vaccine—built in collaboration with the University of Oxford—and its FDA-approved treatment, Evusheld. The work earned him a British order of chivalry.  Prior to joining AstraZeneca in 2019, Marshall spent more than 16 years at GSK, rising through the ranks from director of clinical pharmacology to medicines development leader. He left GSK in 2019 to become chief medical officer at Galecto Biotech, a role he kept for just more than a year.  Juvenescence dubs itself as an anti-aging therapeutics company, a broad aspiration that centers on developing therapies via a variety of modalities like regenerative medicine or metabolism revival. The company launched in 2017 and raised $100 million two years later to advance its programs. The company’s lead asset, LyGenesis, is in a phase 2 trial to treat end-stage liver disease. Source > Margit Janát-Amsbury, M.D., Ph.D., has left her role as Amgen’s executive medical director of early oncology development to serve as Halia Therapeutics’ chief medical officer. Before making the jump from Amgen, where she was also product team lead for the Big Pharma’s prostate portfolio, Janát-Amsbury oversaw the development of several small molecules at Tolero Pharmaceuticals, which was acquired in 2017 by Sumitomo Dainippon Pharma. Release > Kristof Van Emelen, Ph.D., is taking the scenic route, diverting from his journey at Ermium Therapeutics to forge a new path at Scenic Biotech. Van Emelen joins Scenic to serve as VP of drug discovery and will oversee development of the company’s pipeline of genetic modifier candidates. Release > Clinical-stage biotech Dianthus Therapeutics has tapped Susan Kalled, Ph.D., to serve as the company’s first chief scientific officer. Before Dianthus, Kalled was CSO of Compass Therapeutics and VP of biology at Q32 Bio. She has also served as senior director of external sciences at Shire, which was acquired by Takeda in 2019. Release > NeuroBo Pharmaceuticals has appointed Joseph Hooker as interim CEO and president after former leader Gil Price, M.D., retired. Hooker has served as an independent consultant in the industry, and most recently served as senior director of clinical operations and program leader for rare disease and oncology at X4 Pharmaceuticals. He also has worked in various roles across Biogen, Pierian Bioscience, MedAvante-ProPhase, Novartis’ Sandoz division and DuPont-Merck Pharmaceuticals, among others. Release > Kevin Heller, M.D., is jumping from his role at Jasper Therapeutics, where he was EVP of R&D, to serve as Tallac Therapeutics’ chief medical officer. Heller’s leadership track record includes names such as NextCure, Incyte, AstraZeneca and Bristol Myers Squibb. Release > Massachusetts biotech Parallel Bio has pulled in several new team leaders, including GSK vet Dwight Morrow, Ph.D., to serve as VP and head of platform. Most recently, Morrow was VP of platform innovation for Rubius Therapeutics and has also led preclinical development at Magenta Therapeutics. Before that, he held numerous positions at GSK from 2000 to 2016. Parallel has also added its first scientific advisers: Darrell Irvine, Ph.D., professor at Massachusetts Institute of Technology and investigator with the Howard Hughes Medical Institutes, and Nima Aghaeepour, Ph.D., associate professor and associate vice chair of research and data science at Stanford University. Release > Immunotherapy-focused biotech Normunity has tapped Olga Granaturova to serve as both chief operating officer and chief business officer. Previously, she served as Parthenon Therapeutics’ co-founder and chief operating officer, VP of business development at Evotec, as well as founder and managing partner of life sciences consulting firm LENUS Group. Earlier on, Granaturova held roles at Big Pharmas Merck and Pfizer. Release  > Private biotech Indapta Therapeutics has appointed Moya Daniels as SVP of regulatory, quality and clinical operations. She most recently served as SVP of regulatory and quality at Aruvant Therapeutics and has experience at several biotechs, including Orchard Therapeutics, Histogen and Fate Therapeutics. Release > Canada’s Appili Therapeutics has tapped two new leaders to help support development for its biodefense vaccine program. Carl Gelhaus, Ph.D., will step aboard as Appili’s director of nonclinical research while Arthur Baran will become director of new product development and oversee ATI-1701, a potential first-in-class vaccine candidate for preventing infection with aerosolized Francisella tularensis, which the National Institutes of Health has classified as a category A pathogen and top-priority biothreat. Release > Alessandro Monge, Ph.D., has joined tech company TandemAI to serve as chief business officer. Before joining TandemAI, which aims to transform drug discovery infrastructure, Monge served as SVP and head of U.S. operations at Iktos. He also served as VP of strategic business at Schrödinger and was co-founder, president and CEO for ProCeryon Biosciences. Release